<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322462</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A23</org_study_id>
    <nct_id>NCT03322462</nct_id>
  </id_info>
  <brief_title>Tau Screening Study in Patients With Early Symptomatic AD</brief_title>
  <official_title>A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to serve as a pre-screening study for subjects who are potentially&#xD;
      eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for&#xD;
      inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flortaucipir Qualitative Results (Visual Reads)</measure>
    <time_frame>baseline scan</time_frame>
    <description>Flortaucipir PET scans were rated visually by an expert reader as follows: Not consistent with an AD pattern (τAD-), Moderate AD pattern (τAD+), or Advanced AD pattern and likely to progress (τAD++). Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flortaucipir Quantitative Results (SUVr)</measure>
    <time_frame>baseline scan</time_frame>
    <description>Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. Visual read categories as described for previous measure. Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Flortaucipir PET Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flortaucipir F18</intervention_name>
    <description>370 megabecquerel (MBq) IV single-dose</description>
    <arm_group_label>Flortaucipir PET Scan</arm_group_label>
    <other_name>18F-AV-1451</other_name>
    <other_name>[F-18]T807</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain PET Scan</intervention_name>
    <description>positron emission tomography (PET) scan of the brain</description>
    <arm_group_label>Flortaucipir PET Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women between the ages of 60 and 85 years of age at the time of consent&#xD;
&#xD;
          -  Patients with gradual and progressive change in memory function for a period equal to&#xD;
             or greater than six months&#xD;
&#xD;
          -  Patients who have a Mini Mental State Examination (MMSE) score in the 20-27 range&#xD;
&#xD;
          -  Patients who are willing to undergo a PET scan using flortaucipir F 18&#xD;
&#xD;
          -  Patients who give informed consent or have a legally authorized representative (LAR)&#xD;
             to consent for enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who lack adequate premorbid literacy, vision, or hearing to complete the&#xD;
             required psychometric testing in the investigator's opinion&#xD;
&#xD;
          -  Females of childbearing potential who are not surgically sterile, not refraining from&#xD;
             sexual activity, or not using reliable contraception methods. Females of childbearing&#xD;
             potential must not be pregnant (negative serum β-Human Chorionic Gonadotropin [HCG] at&#xD;
             screening and negative urine β-HCG prior to flortaucipir F 18 injection) or&#xD;
             breastfeeding at screening. Females should agree to avoid becoming pregnant by&#xD;
             refraining from sexual activity or using reliable contraceptive methods for 24 hours&#xD;
             following flortaucipir F 18 injection administration.&#xD;
&#xD;
          -  Have significant neurological disease affecting the Central Nervous System (CNS)&#xD;
             (other than AD) that may affect cognition or ability to complete the study, including&#xD;
             but not limited to, other types of dementia, serious brain infections, Parkinson's&#xD;
             disease, multiple concussions, or epilepsy or recurrent seizures (except febrile&#xD;
             childhood seizures).&#xD;
&#xD;
          -  Patients with any current primary psychiatric diagnosis other than AD if, in the&#xD;
             opinion of the investigator, the disorder/symptom is likely to confound interpretation&#xD;
             of drug effect, affect cognitive assessment, or affect the patient's ability to&#xD;
             complete the study (patients with history of schizophrenia or other chronic psychosis&#xD;
             are excluded).&#xD;
&#xD;
          -  Intend to use drugs known to significantly prolong the QT interval within 14 days or 5&#xD;
             half-lives (whichever is longer) of a scheduled screening/baseline flortaucipir F 18&#xD;
             PET scan, or have medical history of risk factors for Torsades du Pointes.&#xD;
&#xD;
          -  Have an average electrocardiography (ECG) corrected QT (QTcF) interval measurement &gt;&#xD;
             450 msec (men) or &gt; 470 msec (women) at screening (as determined at the&#xD;
             investigational site).&#xD;
&#xD;
          -  Have ocular pathology that significantly limits ability to reliably evaluate vision or&#xD;
             the retina.&#xD;
&#xD;
          -  Have a history of alcohol or drug disorder (except tobacco use disorder) within 2&#xD;
             years before the screening visit&#xD;
&#xD;
          -  Have a current serious or unstable illness including retinal, cardiovascular, hepatic,&#xD;
             renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD),&#xD;
             psychiatric, immunologic, or hematologic disease and other conditions that, in the&#xD;
             investigator's opinion, could interfere with the analyses in this study; or has a life&#xD;
             expectancy of less than 24 months.&#xD;
&#xD;
          -  Has a history of cancer within the last five years, with the exception of&#xD;
             non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical&#xD;
             cancer, non-progressive prostate cancer, or other cancers with low risk of recurrence&#xD;
             or spread&#xD;
&#xD;
          -  Patients with a past history (suspected or confirmed) of Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  History of vitiligo and/or current evidence of post-inflammatory hypopigmentation&#xD;
&#xD;
          -  Have had prior treatment with a passive anti-amyloid immunotherapy less than five&#xD;
             half-lives prior to randomization.&#xD;
&#xD;
          -  Have previously participated in any other study investigating active immunization&#xD;
             against amyloid beta (Aβ)&#xD;
&#xD;
          -  Patients that are currently enrolled in any other interventional clinical trial&#xD;
             involving an investigational product or any other type of medical research judged not&#xD;
             to be scientifically or medically compatible with this study&#xD;
&#xD;
          -  Contraindication to PET&#xD;
&#xD;
          -  Has hypersensitivity to flortaucipir F 18 or any of its excipients&#xD;
&#xD;
          -  Present or planned exposure to ionizing radiation that, in combination with the&#xD;
             planned administration of study PET ligands, would result in a cumulative exposure&#xD;
             that exceeds local recommended exposure limits&#xD;
&#xD;
          -  Has previous magnetic resonance imaging (MRI) evidence of significant abnormality that&#xD;
             would suggest another potential etiology for progressive dementia or a clinically&#xD;
             significant finding that may impact patient's potential to safely participate in study&#xD;
&#xD;
          -  Have contraindications for MRI, including claustrophobia or the presence of&#xD;
             contraindicated metal (ferromagnetic) implants/cardiac pacemaker&#xD;
&#xD;
          -  Have poor venous access&#xD;
&#xD;
          -  Are investigator site personnel directly affiliated with this study and/or immediate&#xD;
             families; immediate family is defined as a spouse, parent, child, or sibling&#xD;
             (biological or legally adopted)&#xD;
&#xD;
          -  Are Lilly employees or are employees of third-party organizations (TPOs) involved in a&#xD;
             study that requires exclusion of their employees&#xD;
&#xD;
          -  Are otherwise unsuitable for a study of this type in the opinion of the investigator&#xD;
&#xD;
          -  Have received treatment with a stable dose of an acetylcholinesterase inhibitor&#xD;
             (AChEI) and/or memantine for less than two months before randomization (if a patient&#xD;
             has recently stopped an AChEI and/or memantine, he/she must have discontinued&#xD;
             treatment at least two months before randomization).&#xD;
&#xD;
          -  Current use of strong inducers of CYP3A&#xD;
&#xD;
          -  Are currently on medication(s) known to significantly prolong the QT interval&#xD;
&#xD;
          -  Have allergies to either monoclonal antibodies, diphenhydramine, epinephrine, or&#xD;
             methylprednisolone&#xD;
&#xD;
          -  Have known allergies to LY3002813, related compounds, or any components of the&#xD;
             formulation; or history of significant atopy&#xD;
&#xD;
          -  Have known allergies to LY3202626, related compounds, or any components of the&#xD;
             formulation&#xD;
&#xD;
          -  Changes in concomitant medications that could potentially affect cognition and their&#xD;
             dosing should be stable for at least one month before screening, and between screening&#xD;
             and randomization (does not apply to medications discontinued due to exclusions or&#xD;
             with limited duration of use, such as antibiotics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica (Compass Research)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <results_first_submitted>June 27, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2020</results_first_posted>
  <disposition_first_submitted>August 29, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 7, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 24, 2020</disposition_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03322462/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03322462/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment occurred between Nov 2017 and Aug 2018. Recruited subjects with clinically diagnosed early AD who were interested in participating in AD therapeutic clinical trial AACG (Eli Lilly and Company; TRAILBLAZER-ALZ; NCT03367403)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Early Symptomatic AD Subjects</title>
          <description>Early Symptomatic AD subjects in the flortaucipir PET scan arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Flortaucipir PET Scan</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Technical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Symptomatic AD Subjects</title>
          <description>Early Symptomatic AD subjects in the flortaucipir PET scan arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MMSE</title>
          <description>Mini-mental status exam (MMSE) is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flortaucipir Qualitative Results (Visual Reads)</title>
        <description>Flortaucipir PET scans were rated visually by an expert reader as follows: Not consistent with an AD pattern (τAD-), Moderate AD pattern (τAD+), or Advanced AD pattern and likely to progress (τAD++). Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.</description>
        <time_frame>baseline scan</time_frame>
        <population>Includes all subjects who completed the study with valid flortaucipir PET scan (n=152)</population>
        <group_list>
          <group group_id="O1">
            <title>Early Symptomatic AD, Eligible for AACG Study</title>
            <description>Subjects determined to be eligible for the AACG Study from the flortaucipir PET scan arm.</description>
          </group>
          <group group_id="O2">
            <title>Early Symptomatic AD, Ineligible for AACG Study</title>
            <description>Subjects who were not eligible for the AACG Study from the flortaucipir PET scan arm.</description>
          </group>
          <group group_id="O3">
            <title>Early Symptomatic AD (Total)</title>
            <description>All subjects with early symptomatic AD from the flortaucipir PET scan arm</description>
          </group>
        </group_list>
        <measure>
          <title>Flortaucipir Qualitative Results (Visual Reads)</title>
          <description>Flortaucipir PET scans were rated visually by an expert reader as follows: Not consistent with an AD pattern (τAD-), Moderate AD pattern (τAD+), or Advanced AD pattern and likely to progress (τAD++). Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.</description>
          <population>Includes all subjects who completed the study with valid flortaucipir PET scan (n=152)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>τAD++, advanced AD pattern</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>τAD+, moderate AD pattern</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>τAD-, pattern not consistent with AD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flortaucipir Quantitative Results (SUVr)</title>
        <description>Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. Visual read categories as described for previous measure. Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.</description>
        <time_frame>baseline scan</time_frame>
        <population>SUVr was not collected for patients with a τAD- result</population>
        <group_list>
          <group group_id="O1">
            <title>Early Symptomatic AD, Eligible for AACG Study</title>
            <description>Subjects determined to be eligible for the AACG Study from the flortaucipir PET scan arm.</description>
          </group>
          <group group_id="O2">
            <title>Early Symptomatic AD, Ineligible for AACG Study</title>
            <description>Subjects who were not eligible for the AACG Study from the flortaucipir PET scan arm.</description>
          </group>
          <group group_id="O3">
            <title>Early Symptomatic AD (Total)</title>
            <description>All subjects with early symptomatic AD from the flortaucipir PET scan arm</description>
          </group>
        </group_list>
        <measure>
          <title>Flortaucipir Quantitative Results (SUVr)</title>
          <description>Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. Visual read categories as described for previous measure. Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.</description>
          <population>SUVr was not collected for patients with a τAD- result</population>
          <units>standardized uptake value ratio (SUVr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SUVr all</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21207" spread="0.119729"/>
                    <measurement group_id="O2" value="1.48576" spread="0.316435"/>
                    <measurement group_id="O3" value="1.30537" spread="0.244527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUVr τAD++ subjects</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21518" spread="0.120696"/>
                    <measurement group_id="O2" value="1.65880" spread="0.143067"/>
                    <measurement group_id="O3" value="1.34031" spread="0.237395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUVr τAD+ subjects</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12490" spread="0.012021"/>
                    <measurement group_id="O2" value="1.00991" spread="0.023239"/>
                    <measurement group_id="O3" value="1.03291" spread="0.052789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours after study drug administration</time_frame>
      <desc>Adverse events (AEs) were collected at scan visits, regardless of attribution to study drug. End of study for AE reporting was 48 hours after the last study drug administration. AEs occurring after study drug administration, but outside that window were not recorded, unless considered attributable to study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Safety Analysis Population</title>
          <description>All subjects with early symptomatic AD from the flortaucipir PET scan arm who received one dose of flortaucipir</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Avid Radiopharmaceuticals, Inc.</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

